Key result
Nimodipine-induced vasoplegia remains a life-threatening complication lacking standardized management protocols.
Why the study?
Profound hypotension secondary to vasoplegia following nimodipine administration for cerebral vasospasm after subarachnoid hemorrhage is a rare, life-threatening complication with only limited case reports and no standardized treatment protocols.
This narrative review explores treatment options for life-threatening vasoplegia induced by nimodipine in patients treated for cerebral vasospasm after subarachnoid hemorrhage.
Answers are grounded in this paper and cite their sources.
May inform adjunctive nitric oxide strategies; leaves open whether novel agents improve outcomes beyond nimodipine in subarachnoid hemorrhage.
Cerebral vasospasm following a subarachnoid hemorrhage is a major complication that leads to delayed cerebral ischemia, which contributes significantly to morbidity and mortality. The process is multifactorial and involves the breakdown of blood products within the subarachnoid space, leading to oxyhemoglobin-mediated endothelial dysfunction and nitric oxide depletion, resulting in subsequent vasoconstriction and impaired cerebral perfusion. The standard of care for patients with subarachnoid hemorrhage has been to administer the dihydropyridine calcium-channel blocker nimodipine as oral nimodipine significantly reduce poor outcomes and delayed cerebral ischemia. Although mild hypotension is a common adverse effect of nimodipine, profound hypotension secondary to vasoplegia following nimodipine administration can be a rare and life-threatening complication. Vasoplegia is thought to result from nitric oxide accumulation following high-dose calcium-channel blocker administration and subsequent systemic vasodilation. Although there have been limited case reports on successful treatment of nimodipine-induced vasoplegia, no standardized treatment protocols currently exist. Thus, this narrative review aimed to explore various treatment options for this serious complication associated with vasospasm treatment following subarachnoid hemorrhage.
No takes yet. Share an insight, caveat, or question.
Passman et al. (2026) conducted a review in Nimodipine-induced vasoplegia during vasospasm treatment after subarachnoid hemorrhage. Nimodipine was evaluated. Nimodipine-induced vasoplegia is a rare, life-threatening complication of subarachnoid hemorrhage treatment for which no standardized treatment protocols currently exist.
Synapse has enriched 10 related papers. Consider them for comparative context: